SEROQUEL is an appropriate choice in the treatment of schizophrenia because:
- SEROQUEL works to control activation and hostility in schizophrenia [1]
- SEROQUEL is effective at improving the positive and negative symptoms of schizophrenia [2, 3]
- SEROQUEL calms symptoms of anxiety and depression in patients with schizophrenia [4]
- SEROQUEL has a well-established tolerability profile [5-7]
Please visit AstraZeneca Clinical Trials - SEROQUEL Section for details of completed and ongoing clinical trial studies involving SEROQUEL.
Learn more about SEROQUEL efficacy and tolerability data.
The site is intended for an international audience of healthcare professionals. If you are in the US please visit SEROQUEL.com. If you are in the UK please visit emc.medicines.org.uk. Patient and carers should go to Patient Health International